
Trust signals
- All dosing figures are sourced from FDA prescribing information or named peer-reviewed trials.
- Speculative or off-label claims are labeled as such throughout.
- No affiliate links to peptide vendors. No financial interest in any sourcing recommendation.
- The FDA-approved dose is 2 mg subcutaneously once daily for HIV-associated lipodystrophy (Egrifta). This is the only human dosage supported by phase III RCT data. No other indication has regulatory approval.
What tesamorelin dosage is used in bodybuilding or physique research protocols?
Unapproved research protocols typically mirror the clinical 1-2 mg per day range, sometimes described as two 1 mg injections. There are no RCTs supporting these uses. Evidence is anecdotal or extrapolated from lipodystrophy trials.
How do you mix tesamorelin 2mg vials?
Add approximately 2.0-2.1 mL of sterile water for injection (or bacteriostatic water for multi-dose use) to a 2 mg lyophilized vial, yielding approximately 1 mg/mL. Swirl gently; never shake. Draw 1.0 mL for a 1 mg dose or 2.0 mL for the full 2 mg clinical dose.
What does a tesamorelin 10mg vial contain and how is it dosed?
10 mg vials are a research-grade format not FDA-approved. Reconstituted with 10 mL bacteriostatic water yields 1 mg/mL. Each 1.0 mL draw equals 1 mg (1000 mcg). Verify purity via third-party COA before any use.
What is the tesamorelin dosage per day for visceral fat reduction?
Phase III trials (Falutz et al., 2010) used 2 mg once daily subcutaneously and demonstrated statistically significant visceral adipose tissue reduction versus placebo at 26 weeks. Lower doses have not been validated in RCTs for this outcome.
How does tesamorelin compare to CJC-1295 or sermorelin at equivalent doses?
Tesamorelin is the only GHRH analog with phase III human RCT data for a specific clinical outcome. CJC-1295 and sermorelin lack equivalent-quality evidence for fat reduction. Tesamorelin's half-life (~26 minutes) is longer than sermorelin (~12 minutes) but far shorter than CJC-1295 with DAC (days), which blunts natural GH pulsatility.
Is tesamorelin 5mg a standard dosing unit?
5 mg is a research-supply vial size, not an FDA-approved format. Reconstituting 5 mg in 5.0 mL bacteriostatic water gives 1 mg/mL. At the clinical daily dose of 2 mg, each vial provides approximately 2.5 days of dosing.
What happens to tesamorelin stability after reconstitution?
The Egrifta prescribing information states reconstituted solution should be used immediately or refrigerated and used within 24 hours. Bacteriostatic water extends usable window for research vials, but oxidation and aggregation accelerate above 4 degrees Celsius. Never freeze reconstituted peptide.
Does tesamorelin require cycling?
Clinical trial data used continuous daily dosing up to 52 weeks. No mandatory cycling protocol is established by evidence. Discontinuation in trials led to visceral fat returning toward baseline, suggesting effects are maintenance-dependent, not permanent.
What injection site and timing is recommended for tesamorelin?
Subcutaneous injection into the abdomen is the approved route. Morning administration before food is a common clinical convention aligned with natural GH pulsatility, but no head-to-head timing trial exists for tesamorelin specifically.
What are the main safety signals at standard tesamorelin doses?
Phase III data identified injection-site reactions, fluid retention (edema, arthralgia), and IGF-1 elevation as the most common adverse events. Glucose intolerance risk is a documented concern requiring monitoring, particularly in those with pre-diabetic metabolic status.
How do I read a tesamorelin COA for purity?
Look for HPLC purity above 98%, mass spectrometry confirmation of correct molecular weight (5135.9 Da for tesamorelin), and endotoxin testing below 1 EU/mg. A COA lacking MS confirmation or endotoxin data is insufficient for any injected use.
Sources
- Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370.
- Falutz J, Potvin D, Mamputu JC, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr. 2010;53(3):311-322.
- Baker LD, Barsness SM, Borson S, et al. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults. JAMA. 2012;308(1):47-57.
Related peptide guides
From the FormBlends catalog
Tesamorelin
GHRH analog studied for visceral-fat reduction; the molecule was approved as Egrifta · From $249/mo · compounded by a licensed 503A pharmacy, dispensed only after provider review.
View Tesamorelin →
Ready when you are
Tesamorelin
GHRH analog studied for visceral-fat reduction; the molecule was approved as Egrifta · From $249/mo · compounded by a licensed 503A pharmacy, dispensed only after provider review.
View Tesamorelin →